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Relationship of Rapid Rate Nonsustained
Ventricular Tachycardia to Outcomes
in the SCD-HeFT StudyThe paper by Chen et al. (1) on the relevance of rapid rate non-
sustained ventricular tachycardia (RR-NSVT) noted on routine
deﬁbrillator follow-up is intriguing. Figure 3 in the article dem-
onstrated an inappropriate shock for an episode of RR-NSVT that
self-terminated but for which the device was “committed” to
delivering therapy. A question for the authors is what role did such
shocks play in their ﬁnding of increased mortality with these
episodes? They note that nearly 5% of patients received inappro-
priate therapy. Did the mortality results change signiﬁcantly if
patients were stratiﬁed by shock appropriateness? This is particu-
larly relevant in light of the dramatic ﬁndings of the MADIT-RIT
(Multicenter Automatic Deﬁbrillator Implantation Trial-Reduce
Inappropriate Therapy) trial (2) and could provide further
evidence that a minimalist approach to deﬁbrillator therapy is best
for patient outcomes.*Richard Z. Andraws, MD
*Gagnon Cardiovascular Institute at Atlantic Health and
Central New Jersey Cardiology
1511 Park Avenue
Suite 2
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Tachycardia Found on ICD Interrogation:
Relationship of RR-NSVT to Outcomes
in the SCD-HeFT TrialWe appreciate the interest in our paper and the opportunity to reply
to Dr. Andraws’ most thoughtful comments (1).
It is very difﬁcult to isolate the different facets of the rapid-rate
nonsustained ventricular tachycardia (RR-NSVT) and inappro-
priate shock-mortality relationships. In fact, it is likely that these
relationships are not entirely independent of one another. Patients
could have a widely varying number of RR-NSVT episodes as well
as multiple inappropriate (and appropriate) shocks, and these
events could have happened in any possible order over a range of
time intervals. Earlier events may have had an impact on later
events. A model that attempts to capture all of the variable
relationships would be impossible to interpret.
A recent study by Powell et al. (2), from the Boson Scientiﬁc–
sponsored ALTITUDE database demonstrated that inappropriate
implantable cardioverter-deﬁbrillator (ICD) shocks from sinus
tachycardia, sustained ventricular tachycardia, noise artifact, or
oversensing did not increase mortality, whereas inappropriate ICD
shocks from NSVT did increase mortality (as well as shocks for
ventricular tachycardia/ventricular ﬁbrillation/atrial ﬁbrillation).
This suggests that it may be the substrate and arrhythmias, not the
shocks themselves, that are the primary contributors to the
increased mortality that has been observed in such patients.
In a previous analysis from the SCD-HeFT (Sudden Cardiac
Death in Heart Failure Trial), appropriate and inappropriate shocks
were both found to be independently associated with an increase in
mortality (3). In that analysis, NSVT was included in the category
of inappropriate shocks (example illustrated in Figure 3 of our
paper), where the RR-NSVT terminated, but the ICD delivered
shock therapy due to the conﬁrmation algorithm used in that
generation of Medtronic ICD (model 7223). These data, taken
together, strongly support longer detection times in an effort to
minimize unneeded ICD therapy.
